Cologuard® Wins Popular Science Magazine's 2014 "Best of What's New" Award

Exact Sciences' new colon cancer screening test recognized as a revolution in healthcare

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS) today announced Cologuard has received a 2014 "Best of What's New" award from Popular Science.

Cologuard is the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. Approved by the FDA in August, Cologuard detects the presence of cancer and precancer by analyzing both DNA and blood in the stool.

"Exact Sciences is honored to receive this recognition from the editors of Popular Science," said Kevin Conroy, Chairman and CEO of Exact Sciences. "The 'Best of What's New' list recognizes the groundbreaking potential of Cologuard to improve the colon cancer screening rates and enable survival from a disease that is often considered the most preventable, yet least prevented cancer due to the lack of patient compliance with screening."

Colorectal cancer is highly treatable with early detection through screening. However, 23 million Americans between 50 and 75 are not getting screened as recommended and, as a result, colorectal cancer remains the second-leading cancer killer in the United States. For those whose cancer is detected at an earlier stage, the five-year survival rate can be greater than 90 percent.

Cologuard, which is available by prescription, offers people 50 years and older, who are at average risk for colorectal cancer, an easy to use screening test, which they can do in the privacy of their own home. Cologuard has been proven to find 92 percent of colorectal cancers in average risk patients with 87 percent specificity. Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both stool-based biomarkers including DNA and blood to detect cancer and precancer.

Each year, editors of Popular Science review thousands of new products and innovations of the year and choose the top 100 winners across 12 categories for inclusion in their annual "Best of What's New" issue. To win, a product or technology must represent a significant step forward in its category. All of the winners are featured on the Popular Science website, and in the special Popular Science December issue, on newsstands today.

About Exact Sciences Corp.

Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, , follow us on Twitter @ExactSciences or find us on Facebook.

Rx only.

About Popular Science

Founded in 1872, Popular Science is the worldʼs largest science and technology magazine; with a circulation of 1.3 million and 6.8 million monthly readers. Each month, Popular Science reports on the intersection of science and everyday life, with an eye toward whatʼs new and why it matters. Popular Science is published by Bonnier Active Media, a subsidiary of Bonnier Corporation.

Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.Forward-looking statements in this news release may address the following subjects among others: statements regarding the sufficiency of our capital resources, our ability to secure favorable reimbursement rates from Medicare and other third-party payors, timing of our launch of a commercial product, our estimates of the available market size and our potential penetration, expected research and development expenses, expected general and administrative expenses and our expectations concerning our business strategy. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

 

Exact Sciences
Cara Tucker, 614-302-5622
ctucker@exactsciences.com
or
MSLGROUP
781-684-0770
exactsciences@mslgroup.com

Source: Exact Sciences Corp.

News Provided by Acquire Media

Read More

Topics: Exact Sciences News

Exact Sciences Announces Cologuard Will Now Be Available By Prescription Through MDVIP Physicians

BOCA RATON, Fla. & MADISON, Wis.--(BUSINESS WIRE)-- MDVIP, the leader in personalized preventive medicine with a nationwide network of over 750 affiliated primary care physicians, announced today that Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer will now be available by prescription through its physicians. MDVIP is the first personalized healthcare network to partner with Exact Sciences to bring this innovative new test to its primary care physicians.

"MDVIP physicians have traditionally been early adopters of medical innovation," says Dr. Andrea Klemes, Chief Medical Officer of MDVIP. "Cologuard, a significant advancement in colorectal cancer detection, will allow our patients who are 50 years and older and at average risk for colorectal cancer, an easy to use screening test which they can do in the privacy of their own home."

Read More

Topics: Exact Sciences News

Exact Sciences Announces Mayo Clinic as First Healthcare System to Offer Cologuard®

Stool-based DNA (sDNA) screening test for colorectal cancer to be available by prescription to patients

MADISON, Wis. & ROCHESTER, Minn.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Mayo Clinic will be the first health system to offer Cologuard®, the first and only Food and Drug Administration (FDA) approved, noninvasive stool DNA screening test for colorectal cancer. Cologuard will be available to patients through their primary care physicians at Mayo Clinic.

Read More

Topics: Exact Sciences News

FDA Approves Exact Sciences’ Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test

Exact Sciences Corp. (NASDAQ: EXAS) announced today that the U.S. Food and Drug Administration (FDA) has approved Cologuard, the company’s noninvasive, stool DNA colorectal cancer screening test. Cologuard is the first noninvasive screening test for colorectal cancer that analyzes both stool DNA and blood biomarkers and has been proven to find 92 percent of cancers and 69 percent of the most advanced precancerous polyps in average risk patients. Cologuard, which is available through healthcare providers, offers people 50 and older at average risk for colorectal cancer an easy–to–use screening test they can do in the privacy of their own home.

Read More

Topics: Exact Sciences News